Predict your next investment

EpiVax company logo
Corporation
HEALTHCARE | Biotechnology
epivax.com

See what CB Insights has to offer

Founded Year

1998

Stage

Loan | Alive

Total Raised

$23.95M

Last Raised

$680K | 1 yr ago

About EpiVax

EpiVax, is a privately held biotechnology company focused on the development of vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. The immunoinformatics team at EpiVax has developed the cloud-based ISPRI and iVAX toolkits, used by a global roster of companies to design and optimize therapeutic proteins and vaccines. More at www.epivax.com.

EpiVax Headquarter Location

146 Clifford St

Providence, Rhode Island, 02903,

United States

401-272-2123

Latest EpiVax News

08:48 ET Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

Jul 6, 2021

News provided by Share this article Share this article PROVIDENCE, R.I., July 6, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce that Dr. Amy Rosenberg is leaving the FDA's Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics. Dr. Rosenberg's work has focused on immune tolerance induction and immunogenicity. At the FDA, she oversaw the regulation and approval of numerous protein therapeutics and served as expert consultant to the National Institute of Health's Immune Tolerance Network. Other notable appointments include: Oncology Center of Excellence Science Council EpiVax CEO/CSO, Dr. Annie De Groot, is looking forward to Rosenberg's start: "Dr. Rosenberg is a key opinion leader for many 'classical' biologic products such as erythropoietin, G/GM-CSF, mAbs, as well as cellular therapies, and has been exploring novel biologics such as CAR-T and TIL cell therapies. Amy and I look forward to sharing her vast experience with EpiVax aficionados during our ' Fearless Science World tour ' this fall and winter." Dr. Rosenberg's years of regulatory experience will strengthen EpiVax's ability to support clients developing vaccines and biologics for regulatory review. Dr. Rosenberg will also work with EpiVax scientists on a range of internal research programs, listed below: Personalized Immunogenicity Assessment for Biologics (PIMA): Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease . EpiVax applied in silico tools (EpiMatrix and JanusMatrix) to identify immunogenic and tolerogenic epitopes that are recognized by individual Pompe patients and predicted based on their acid alpha-glucosidase (GAA) gene and HLA DR haplotype. De Groot AS et al., Frontiers in Immunology, 16 June 2021. Regarding her move to EpiVax, Dr. Rosenberg said, "I am thrilled to join this pioneering immunologically focused company exploring the range of applications of novel immunoinformatic technologies for evaluating and improving immune based outcomes for the most pressing issues and diseases of our time: infectious diseases, cancer, and autoimmunity as well as to find the means to deimmunize or tolerize to gene and protein therapeutics in the context of enzyme/gene replacement therapies for rare diseases." About EpiVax: EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening toolkits for therapeutics (ISPRI)  and vaccines (iVAX) , are employed in advancing the research of a global roster of companies. Press Contact: EpiVax

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EpiVax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EpiVax is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

EpiVax Patents

EpiVax has filed 26 patents.

The 3 most popular patent topics include:

  • Immunology
  • Immune system
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/16/2018

6/29/2021

Immunology, Immune system, Clusters of differentiation, Monoclonal antibodies, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/16/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/29/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Immunology, Immune system, Clusters of differentiation, Monoclonal antibodies, Transcription factors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

EpiVax Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EpiVax Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.